


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. - 116. (cancelled)

117. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formula A1, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:



wherein

- Y represents O, S or NR₄;
- R₁, R₂ and R₄ are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;

- R3 is selected from hydrogen, unsubstituted or substituted methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and tert.-butyl, unsubstituted or substituted, straight chain or branched C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A1 via a C atom or a heteroatom.

118. (new) The composition of claim 117, wherein R3 is selected from substituted methyl, ethyl, n-propyl and i-propyl.

119. (new) The composition of claim 117, wherein R3 is selected from substituted methyl and substituted ethyl.

120. (new) The composition of claim 117, wherein Y represents O.






121. (new) The composition of claim 117, wherein R1 represents hydrogen.







122. (new) The composition of claim 117, wherein R2 represents hydrogen.

P29677.A06

123. (new) The composition of claim 118, wherein R1 and R2 represent hydrogen and Y represents O.


124. (new) The composition of claim 117, wherein the composition comprises at least one active ingredient selected from compounds of the following formulae, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

A1.001	
A1.002	
A1.003	
A1.004	
A1.005	

A1.006	
A1.008	
A1.010	
A1.012	
A1.013	
A1.014	

P29677.A06

125. (new) The composition of claim 117, wherein the composition comprises a compound of the following formula, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:



126. (new) The composition of claim 117, wherein the composition further comprises one or more inhibitors of dipeptidyl peptidase IV.

127. (new) The composition of claim 123, wherein the composition further comprises one or more inhibitors of dipeptidyl peptidase IV.

128. (new) A method of treating at least one chronic neuronal disease in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 117 in an amount sufficient for treating the at least one chronic neuronal disease.

129. (new) The method of claim 128, wherein the chronic neuronal disease comprises at least one of Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Parkinson's disease, Huntington's disease, prion-caused diseases and amyotrophic lateral sclerosis.

P29677.A06

130. (new) The method of claim 129, wherein the chronic neuronal disease comprises Parkinson's disease coupled to chromosome 17.

131. (new) A method of treating at least one chronic neuronal disease in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 123 in an amount sufficient for treating the at least one chronic neuronal disease.

132. (new) The method of claim 131, wherein the chronic neuronal disease comprises at least one of Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Parkinson's disease, Huntington's disease, a prion-caused disease and amyotrophic lateral sclerosis.

133. (new) A method of treating at least one chronic neuronal disease in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 124 in an amount sufficient for treating the at least one chronic neuronal disease.

134. (new) The method of claim 133, wherein the chronic neuronal disease is at least one of Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Parkinson's disease, Huntington's disease, a prion-caused disease and amyotrophic lateral sclerosis.

P29677.A06

135. (new) A method of treating at least one chronic neuronal disease in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 125 in an amount sufficient for treating the at least one chronic neuronal disease.

136. (new) The method of claim 135, wherein the chronic neuronal disease is at least one of Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Parkinson's disease, Huntington's disease, a prion-caused disease and amyotrophic lateral sclerosis.